Analyst Ratings for BioNTech
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 Wall Street analysts have published their ratings on BioNTech (NASDAQ:BNTX), with 2 bullish and 3 indifferent ratings. The average 12-month price target for BNTX is $129.0, with a high of $180.00 and a low of $110.00. This average has decreased by 2.64% from the previous target of $132.50. Analysts typically review stocks quarterly or after major company updates, basing their predictions on financial forecasts and company performance.
November 14, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioNTech received 2 bullish and 3 neutral ratings from analysts with an average price target of $129, a decrease from the previous $132.50 target.
The mixed analyst ratings with a majority being neutral suggest a consensus of cautious optimism or uncertainty about BNTX's future performance. The slight decrease in the average price target may indicate a minor adjustment in expectations, but not a significant change in sentiment. This could lead to a neutral short-term impact on the stock price as the market digests these ratings.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100